Abstract：【Objective】To investigate the effects of Apatinib combined with transcatheter arterial chemoembolization (TACE) on serum alpha-fetoprotein (AFP),carbohydrate antigen 125 (CA125) and carbohydrate antigen 199 (CA199) in patients with advanced liver cancer. 【Methods】A total of 86 patients with advanced liver cancer who admitted to our hospital were divided into the observation group and the control group according to random number table method,with 43 cases in each group. Both groups received TACE treatment,while the observation group was additionally treated with Apatinib. After 3 months of treatment,the therapeutic effect,occurrence of adverse reactions and serum levels of AFP,CA125 and CA199 were compared between the two groups. The 1-year follow-up was performed to compare the 1-year survival rate between the two groups. 【Results】There was no significant difference in objective remission rate and disease control rate between the two groups after 3 months of treatment (P>0.05). Serum AFP,CA125 and CA199 levels in both groups after treatment were significantly lower than those before treatment (P<0.05); And AFP,CA125 and CA199 levels of post-treatment in the observation group was lower than those in the control group after treatment (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05). The 1-year survival rate of observation group was 71.43%(30/42) which was higher than that of control group 51.16% (22/43),and the difference was statistically significant (P<0.05). 【Conclusion】Apatinib combined with TACE in the treatment of patients with advanced liver cancer has a good effect on tumor growth inhibition. It can reduce the levels of serum AFP,CA125 and CA199 without increasing adverse reactions. The 1-year survival rate of patients is higher.
[1] 吴姗姗,王振常,吕艳杭,等. 柔肝化纤解毒方治疗原发性肝癌TACE术后综合征的临床疗效观察[J].中华中医药杂志,2021,36(5):3038-3041.
[2] 赖军明,胡爽,林红,等. 重组人血管内皮抑制素联合TACE治疗中晚期原发性肝癌近期疗效的荟萃分析[J].中华肝胆外科杂志,2019,25(5):358-362.
[3] 龚子永,丁敏,侯建新. 阿帕替尼联合化疗治疗晚期乳腺癌的疗效及安全性[J].癌症进展,2020,18(20):2095-2098.
[4] 中国抗癌协会肝癌专业委员会,中华医学会肝病学分会肝癌学组,中国抗癌协会病理专业委员会,等. 原发性肝癌规范化病理诊断指南(2015年版)[J].中华肝脏病杂志,2015,23(5):321.
[5] 翁志成,彭建扬,吴伟达,等. 阿帕替尼联合S-TACE治疗中晚期原发性肝癌的疗效及安全性评价[J].癌症进展,2019,17(22):2666-2669.
[6] 王健,李荣军,徐春霞,等. 索拉菲尼联合TACE治疗中晚期原发性肝癌的疗效观察及对患者血清AFP、VEGF水平的影响[J].标记免疫分析与临床,2019,26(4):641-644.
[7] CHEN W ,PENG J ,YE J ,et al. Aberrant AFP expression characterizes a subset of hepatocellular carcinoma with distinct gene expression patterns and inferior prognosis[J].J Cancer,2020,11(2):403-413.
[8] YU K.Risk factors for intraocular metastasis of primary liver cancer in diabetic patients:Alpha-fetoprotein and cancer antigen 125[J].World J Diabetes,2021,12(2):158-169.
[9] EDOO M I A ,CHUTTURGHOON V K ,WUSU-ANSAH G K,et al.Serum biomarkers AFP,CEA and CA19-9 combined detection for early diagnosis of hepatocellular carcinoma[J].Iran J Public Health,2019,48(2):314-322.
[10] 曾云建,毛颖民,史自立,等. 聚乙烯醇化疗栓塞联合阿帕替尼治疗晚期原发性肝癌合并动静脉分流的效果[J].介入放射学杂志,2019,28(10):949-953.
[11] 王俊镔,张晶,卢冬彦,等. 阿帕替尼联合经导管肝动脉灌注化疗栓塞治疗中晚期肝癌临床研究的系统评价[J].安徽医药,2019,23(12):2504-2510.
[12] 张学贤,万程,赵卫,等. DEB-TACE联合阿帕替尼治疗肝癌伴门脉癌栓的有效性及安全性[J].介入放射学杂志,2021,30(3):282-287.
[13] LIN Y ,ZHAI E ,LIAO B ,et al. Autocrine VEGF signaling promotes cell proliferation through a PLC-dependent pathway and modulates apatinib treatment efficacy in gastric cancer[J].Oncotarget,2017,8(7):11990-12002.
[14] 凌冰,韩绪生,杨勇,等. 阿帕替尼联合TACE治疗肝癌疗效及对患者血管内皮生长因子和甲胎蛋白的影响[J].现代消化及介入诊疗,2020,25(12):1585-1590.
2023, Vol. 40 
